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Abstract 
Objective 
We investigated the associations between risk of bias judgments from Cochrane reviews for sequence 
generation, allocation concealment and blinding and between-trial heterogeneity.   
 
Study Design and Setting 
Bayesian hierarchical models were fitted to binary data from 117 meta-analyses, to estimate the ratio 
λ by which heterogeneity changes for trials at high/unclear risk of bias, compared to trials at low risk 
of bias.  We estimated the proportion of between-trial heterogeneity in each meta-analysis that could 
be explained by the bias associated with specific design characteristics.   
 
Results 
Univariable analyses showed that heterogeneity variances were, on average, increased among trials at 
high/unclear risk of bias for sequence generation ( λˆ  1.14, 95% interval: 0.57 to 2.30) and blinding ( λˆ  
1.74, 95% interval: 0.85 to 3.47).  Trials at high/unclear risk of bias for allocation concealment were 
on average less heterogeneous ( λˆ  0.75, 95% interval: 0.35 to 1.61).  Multivariable analyses showed 
that a median of 37% (95% interval: 0% to 71%) heterogeneity variance could be explained by trials 
at high/unclear risk of bias for sequence generation, allocation concealment and/or blinding.   All 95% 
intervals for changes in heterogeneity were wide and included the null of no difference.  
 
Conclusion 
Our interpretation of the results is limited by imprecise estimates.  There is some indication that 
between-trial heterogeneity could be partially explained by reported design characteristics, and hence 
adjustment for bias could potentially improve accuracy of meta-analysis results.   
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Introduction  
 
In published meta-analyses, the original studies are often affected by varying amounts of internal bias 
caused by methodological flaws.  Empirical studies have investigated the extent of between-study 
heterogeneity in a meta-analysis [1, 2].  This is likely to comprise a mixture of variation caused by 
true diversity among the study designs, variation due to within-study biases and unexplained 
variation.  For this reason, it would be preferable to separate heterogeneity due to bias from other 
sources of between-study variation, as proposed by Higgins et al. [3]. 
 
Biases associated with reported study design characteristics can be investigated within meta-
epidemiological studies that analyse a collection of meta-analyses.  An early example is that of Schulz 
et al.  [4], where the methodological quality of 250 randomized controlled trials from 33 meta-
analyses within the Cochrane Pregnancy and Childbirth database was assessed.  Schulz et al. provided 
empirical evidence to suggest that trials in which randomization is inadequately concealed report 
exaggerated estimates of intervention effect compared with adequately concealed trials.  There was 
also some indication that trials with inadequate blinding yield larger effect estimates.  
 
More recently, the BRANDO (Bias in Randomized and Observational Studies) study and ROBES 
(Risk of Bias in Evidence Synthesis) study have investigated the associations between reported design 
characteristics and intervention effects and heterogeneity [5, 6]. The BRANDO study combined data 
from all existing meta-epidemiological studies (collections of meta-analyses) into a single database, 
comprising 1973 independent trials included in 234 meta-analyses.  The ROBES database included 
228 binary outcome meta-analyses from Cochrane reviews that had implemented the Cochrane risk-
of-bias tool [7].  In the BRANDO study, all trials included in the database had been categorised 
according to whether they were judged as adequate, inadequate, or unclear for sequence generation, 
allocation concealment and double-blinding.  Trials included in the ROBES study database had been 
categorised as being at high, low or unclear risk of bias for sequence generation, allocation 
concealment, blinding and incomplete outcome data, using the Cochrane risk-of-bias tool.  The results 
of both meta-epidemiological studies showed that the relative intervention effect in favour of the 
experimental treatment is, on average, modestly exaggerated in trials with inadequate randomization 
and lack of blinding.  The ROBES study found no evidence of bias due to a high or unclear risk of 
bias assessment for incomplete outcome data.  Both studies also found that bias in intervention effect 
estimates associated with the lack of blinding in trials with subjective outcome measures may be 
unpredictable in its direction and magnitude, leading to increased within meta-analysis heterogeneity. 
 
  
 
When deciding how to handle suspected biases, meta-analysts often consider whether to restrict their 
analyses to studies at lower risk of bias or to include all available evidence.  Restricting analyses to 
studies at lower risk of bias may lead to an unbiased result, but this result would be imprecise if high 
quality evidence is sparse.  On the other hand, combining all available studies and ignoring flaws in 
their conduct could lead to biased summary estimates with inappropriate clinical or policy decisions 
as a possible consequence.  Welton et al. [8] proposed a method for meta-analysis that uses all 
available data, while adjusting for and down-weighting the evidence from lower quality studies, based 
on evidence from a meta-epidemiological study.   
 
The analyses of BRANDO and ROBES followed methods proposed by Welton et al.[8], which model 
the effects of lower quality design characteristics on average bias and between-trial heterogeneity.  
Under these models, the trials judged to be of poorer quality were assumed to be at least as 
heterogeneous as those of higher quality, which may not be the case.  We have since proposed label-
invariant models that avoid this constraint [9].  Our models are more flexible than the models of 
Welton et al. in allowing us to quantify the ratio by which heterogeneity changes for studies with 
lower quality design characteristics.  This facilitates investigation of how much between-study 
heterogeneity in a meta-analysis is attributable to lower quality studies.   
 
Bias can lead to overestimation or underestimation of the true intervention effect in a study, and we 
could expect differences in risk of bias across studies to contribute to variation among the results of 
studies included in a meta-analysis.  Here we re-analyse trial data from the ROBES database, using 
our label-invariant models to investigate the associations between risk of bias judgments from 
Cochrane reviews and heterogeneity among randomized controlled trials.  We investigate the extent 
of heterogeneity in a meta-analysis that is due to within-trial biases.  The empirical evidence provided 
gives useful information on the extent to which we might expect the between-trial variance to change 
in a meta-analysis, if we adjust for known sources of bias. 
 
Methods  
 
Data description 
We make use of data from the ROBES (Risk of Bias in Evidence Synthesis) [5] study, which is a large 
collection of meta-analyses extracted from the Cochrane Database of Systematic Reviews. These data 
were originally used to examine the associations between reported design characteristics and 
intervention effect estimates in meta-analyses.  Meta-analyses with fewer than five trials were 
excluded, as were meta-analyses where the review authors considered pooling to be inappropriate or 
where numerical data were unavailable.  One or more binary outcome meta-analysis from each 
eligible review was included in the database, corresponding to a primary outcome where possible.  
  
 
The dataset includes 228 meta-analyses from Cochrane reviews that had information on all five of the 
following Risk of Bias items: sequence generation; allocation concealment; blinding; incomplete 
outcome data and selective outcome reporting.  In this paper we do not consider the influence of 
accounting for bias caused by incomplete outcome data or selective outcome reporting on 
heterogeneity.  The ROBES study found no evidence of exaggerated intervention effect among trials 
at high or unclear risk of bias (compared with low risk of bias) for assessment of incomplete outcome 
data [5] and it is not generally recommended to try to adjust for selective outcome reporting bias in 
meta-analysis [10].   
 
Our statistical analyses were carried out on a subset of the ROBES study, comprising 1473 trials from 
117 meta-analyses.  These meta-analyses contained at least one trial at low risk of bias and at least 
one trial at high or unclear risk of bias for each of the three characteristics of interest: sequence 
generation, allocation concealment and blinding.  Focusing on one subset of the data throughout all 
analyses allowed for direct comparison of results assessing the influences of accounting for different 
combinations of study design characteristics on heterogeneity.  Table 1 shows the structure of the 
dataset.  For each trial included in the ROBES database, we have binary outcome data consisting of 
the number of events in each treatment arm and the total number of participants in each arm.  The 
direction of outcome events in the ROBES database is coded such that the outcome for each trial 
corresponds to a harmful event.  All meta-analyses in the database have been categorised according to 
the type of outcome under assessment and the types of interventions evaluated, in the same way as 
Turner et al. [1].  Outcomes in the ROBES database were classified into three broad categories (all-
cause mortality, other objective, subjective) in the same way as the BRANDO study [6].   
 
Table 1  Structure of the dataset 
 N Min Median Max IQR 
No. of trials per 
meta-analysis 
117 meta-analyses 5 10 75 6 to 14 
No. of participants 
per trial 
1473 trials 8 119 182,000 60 to 267 
 
 
Statistical analysis 
 
We used label-invariant hierarchical models to analyse trial data from all included meta-analyses 
simultaneously.  The models were fitted as described in an earlier paper [9] and are based on an 
extension of the model described as “Model 3” by Welton et al. [8].  Within each meta-analysis, a 
model with binomial within-trial likelihoods was fitted to the binary outcome data from each trial on 
  
 
the log odds ratio scale.  The model assumes that the higher quality trials at low risk of bias provide 
an unbiased estimate of intervention effect, assumed to have a normal random-effects distribution 
with variance 2mτ specific to each meta-analysis indexed m.  Throughout our analyses, we used a 
dichotomised variable for each design characteristic (high or unclear risk of bias compared with low 
risk of bias for sequence generation, allocation concealment and blinding).  The trials at high or 
unclear risk of bias are assumed to estimate the sum of two components: the same intervention effect 
as the trials at low risk of bias plus some trial-specific bias.  Within each meta-analysis, we quantify 
variation among trials at high or unclear risk of bias by 2mλτ , which can be lower or higher than the 
variation 2mτ  among trials at low risk of bias.  For each design characteristic, the hierarchical models 
allow us to estimate: the average bias in estimated intervention effect within meta-analysis m (bm); the 
average bias in estimated intervention effect across meta-analyses (b0); the ratio by which between-
trial heterogeneity in intervention effects changes for trials with potential flaws (λ); and variation in 
average bias across meta-analyses (φ).   
 
We first conducted univariable analyses examining the influence of accounting for a single trial 
design characteristic on heterogeneity before carrying out multivariable analyses examining the 
influence of accounting for all three design characteristics.  In multivariable analyses, interactions 
between the different design characteristics were assumed to have distinct variance components λ and 
φ. 
 
Following the approach of Turner et al. [1], we fitted a log-normal model to underlying values of 
heterogeneity variance 2mτ in intervention effect among trials with low risk of bias across meta-
analyses.  Previous research has shown that the extent of total heterogeneity in a meta-analysis differs 
according to the type of outcome examined in the meta-analysis [1, 2].  To investigate association 
between the type of outcome under assessment and the heterogeneity variance among trials with low 
risk of bias, we included indicators for the different types of outcome as covariates in the model for
2
mτ .   
 
All models were fitted using Markov chain Monte Carlo (MCMC) methods within WinBUGS Version 
1.4.3 [11].  We based results on 100,000 iterations, following a burn-in period of 10,000 iterations, 
which was sufficient to achieve convergence and produced low MC error rates.  Convergence was 
assessed according to the Brooks-Gelman-Rubin diagnostic tool [12], using two chains starting from 
widely dispersed initial values.  As in our earlier paper [9], we assigned normal(0,1000) prior 
distributions to location parameters and a log-normal(0,1) prior to λ.  Variation in average bias across 
meta-analyses, φ, was assigned an inverse-gamma(0.001,0.001) prior with increased weight on small 
values.  Model fit was assessed using the deviance information criterion (DIC), as recommended by 
  
 
Spiegelhalter et al. [13,14].  Due to the non-linearity between the likelihood and the model 
parameters, we calculated the effective number of parameters at the posterior mean of the fitted values 
rather than at the posterior mean of the basic model parameters [15].  The WinBUGS code for fitting 
the label-invariant models is available in the Supporting Information of an earlier paper [9]. 
 
 
Quantifying heterogeneity due to bias 
It is of interest to quantify the proportion of between-trial heterogeneity in a meta-analysis that can be 
explained by the bias associated with reported design characteristics.  This requires an estimate of 
total heterogeneity variance among all trials included in a meta-analysis and an estimate of the 
heterogeneity variance after accounting for biases.  The latter is estimated from the model above, 
where the three design characteristics are assumed to be responsible for all of the within-trial biases.  
In univariable analyses for the influence of accounting for a single characteristic, we estimated total 
heterogeneity variance τ 2 ,total m in a meta-analysis m, using the formula
2 2 2 2/ ((1 ) (1 ) )− + + −m m m m m m m mτ π τ π λτ π π b , where πm is the proportion of trials at high or unclear risk of 
bias in meta-analysis m.  The derivation of this formula for total heterogeneity variance is provided in 
Supplementary material (S1), together with the formula used in multivariable analyses for the 
influence of accounting for two characteristics.  We note that the formula used in multivariable 
analyses for the influence of accounting for three characteristics is derived in the same way.  For each 
meta-analysis m within the subset of 117 meta-analyses in ROBES, we used WinBUGS to obtain the 
posterior median for the ratio of between-trial variance among trials at high or unclear risk of bias to 
total between-trial variance 2 2 ,1 /m total m− τ τ .  For each individual design characteristic and all 
combinations of design characteristics, we summarise the proportion of heterogeneity attributable to 
trials at high or unclear risk of bias by the median and 95% interval of posterior medians for 
2 2
,1 /m total m− τ τ across meta-analyses indexed m.    
 
Negative estimates of the proportion of heterogeneity due to trials at high or unclear risk of bias occur 
where the estimate of total heterogeneity variance 2totalτ  among all trials included in a meta-analysis is 
less than the estimate of the heterogeneity variance 2τ among trials at low risk of bias.  We note that 
2
totalτ  is not only increased from 
2τ by the heterogeneity variance among trials at high or unclear risk 
of bias, but also the difference in intervention effect between the trials at high or unclear risk of bias 
and the trials at low risk of bias (see formula in Supplementary material (S1)).  We set the negative 
values of the ratio to zero, since total between-trial heterogeneity in the meta-analysis cannot be 
explained by the trials at high or unclear risk of bias. 
 
  
 
We graphically explored the influence of accounting for reported design characterises on 
heterogeneity on randomized trials in meta-analysis.  For each meta-analysis m within the subset of 
ROBES, we plotted the posterior median of heterogeneity variance 2mτ  among trials at low risk of bias 
against the posterior median of heterogeneity variance τ 2 ,total m  among all trials.   
 
Results 
 
Descriptive analyses 
Table 2 reports the number of trials with each combination of reported design characteristics.   The 
frequency of trials categorised as being at high or unclear risk of bias for a single design characteristic 
was 303 (21%), of which 75 (25%) were at high or unclear risk of bias for sequence generation, 98 
(32%) were at high or unclear risk of bias for allocation concealment and 130 (43%) were at high or 
unclear risk of bias for blinding.  The number of trials categorised as being at high or unclear risk of 
bias for precisely two design characteristics was somewhat higher at 413 (28%).  All three design 
characteristics were judged as high or unclear risk in 396 (27%) of trials.  For each design 
characteristic, Table 2 shows the breakdown of the trial numbers into high risk of bias and unclear 
risk of bias, overall and according to the type of outcome under assessment.  Of all 1473 trials in the 
dataset, sequence generation was assessed as high risk of bias in 41 (3%) trials, unclear in 736 (50%) 
trials, and low risk of bias in 696 (47%) trials.  Allocation concealment was assessed as high risk of 
bias in 80 (5%) trials, unclear in 760 (52%) trials, and low risk of bias in 633 (43%) trials.   Blinding 
was assessed as high risk of bias in 317 (22%) trials, unclear in 383 (26%) trials, and low risk of bias 
in 773 (52%) trials.  The proportions of trials judged as being at high or unclear risk of bias are 
greatest among trials with subjectively measured outcomes, and lowest among trials assessing all-
cause mortality.   
 
  
 
Table 2 The overall number of trials with each combination of reported design characteristics, within the subset of 117 meta-analyses extracted from ROBES, 
and the number of trials at high or unclear risk of bias for each reported design characteristics overall and according to type of outcome measure. 
  
 
  
Risk of bias No. of trials 
(%) 
No. of trials at high risk of bias (% of trials) No. of trials at unclear risk of bias (% of trials) 
Sequence 
generation 
Allocation 
concealment Blinding 
Sequence 
generation 
Allocation 
concealment Blinding 
Sequence 
generation 
Allocation 
concealment Blinding 
Low Low Low 361 (25%) - - - - - - 
High or 
unclear Low Low 75 (5%) 0 - - 75 (100 %) - - 
Low High or unclear Low 98 (7%) - 8 (8%) - - 90 (92%) - 
Low Low High or unclear 130 (9%) - - 75 (58%) - - 55 (42%) 
High or 
unclear 
High or 
unclear Low 239 (16%) 9 (4%) 8 (3%) - 230 (96%) 231 (97%) - 
High or 
unclear Low 
High or 
unclear 67 (5%) 1 (1%) - 28 (42%) 66 (99%) - 39 (58%) 
Low High or unclear 
High or 
unclear 107 (7%) - 19 (18%) 60 (56%) - 88 (82%) 47 (44%) 
High or 
unclear 
High or 
unclear 
High or 
unclear 396 (27%) 31 (8%) 45 (11%) 154 (39%) 365 (92%) 351 (89%) 242 (61%) 
 
Overall 1473 (100%) 41 (3%) 80 (5%) 317 (22%) 736 (50%) 760 (42%) 383 (26%) 
Mortality outcome 271 (18%) 7 (3%) 22 (8%) 76 (28%) 100 (37%) 104 (38%) 36 (13%) 
Objective outcome1 301 (20%) 9 (3%) 13 (4%) 74 (25%) 145 (48%) 152 (51%) 54 (18%) 
Subjective outcome2 901 (61%) 25 (3%) 45 (5%) 167 (19%) 491 (55%) 504 (56%) 293 (33%) 
110 (37%) meta-analyses measured objective outcomes other than all-cause mortality including laboratory assessed outcomes, pregnancy and perinatal outcomes. 17 
(62%) meta-analyses assessed objective outcomes potentially influenced by judgment such as caesarean section and hospital admissions;  2 Subjectively measured 
outcomes include pain, mental health outcomes, cause-specific mortality, clinically-assessed outcomes, signs and symptoms reflecting continuation/end of condition 
and lifestyle outcomes. 
  
 
Model comparison 
Results from model comparison are provided in Supplementary material (S2).   The multivariable 
model for the influence of accounting for high or unclear risk of bias for sequence generation and 
blinding (Model B2) had an improved fit when an interaction term was included.  However, after 
adjustment for trials at high or unclear risk of bias for allocation concealment (Model B4) there was 
no evidence of interaction between sequence generation and blinding.  Despite this, we base our 
results on models including interaction terms among reported design characteristics, because we 
would expect reported design characteristics to interact in practice. 
 
The inclusion of outcome type indicators in the model for heterogeneity variance 2τ did not lead to a 
substantial improvement in model fit.  For this reason, our results are based on hierarchical models for 
2τ  fitted without these covariates.   
 
Exploring the associations between reported trial design characteristics and heterogeneity 
Reported in Table 3 are estimates of λ representing the ratio by which heterogeneity variance changes 
for trials at high or unclear risk of bias for specific design characteristics, compared to trials at low 
risk of bias.   Estimates of average bias (b0) and variation in mean bias across meta-analyses (φ) were 
almost identical to those reported elsewhere [5], and hence not reported here. 
 
Each estimate of λ in Table 3 is very imprecisely estimated; the 95% credible intervals for λ are wide 
and contain the null value 1 representing no difference in heterogeneity among trials at high or 
unclear risk of bias and trials at low risk of bias.   For this reason we interpret the results that follow 
with caution.   
 
Univariable analyses 
Based on univariable analyses for the influence of accounting for a single reported design 
characteristic, variation among trials at high or unclear risk of bias for sequence generation is, on 
average, 14% greater than that among trials at low risk of bias for sequence generation ( λˆ 1.14, 95% 
interval: 0.57 to 2.30).  Heterogeneity among trials judged as high or unclear risk of bias for allocation 
concealment is, on average, 75% that among trials assessed as low risk of bias for allocation 
concealment ( λˆ 0.75, 95% interval: 0.35 to 1.61).  The central estimate for λ suggests that variation 
among trials at high or unclear risk of bias for blinding is, on average, 74% greater than that among 
trials at low risk of bias for blinding ( λˆ 1.74, 95% interval: 0.85 to 3.47).   
 
  
 
Table 3 Results from univariable and multivariable analyses for the influence of accounting for trials at high or unclear risk of bias for specific design 
characteristics on heterogeneity. Posterior medians and 95% intervals are reported. 
 
Model Univariable analyses λ 
 High or unclear risk (vs low risk) of bias for:  
A1  sequence generation 1.14 (0.57 to 2.30) 
A2  allocation concealment 0.75 (0.35 to 1.61) 
A3  blinding 
 
1.74 (0.85 to 3.47) 
 Multivariable analyses (from models including interaction terms)*  
 High or unclear risk (vs low risk) of bias for:  
B1  sequence generation, in trials at low risk of bias for allocation concealment 0.76 (0.14 to 1.79) 
  allocation concealment, in trials at low risk of bias for sequence generation 0.54 (0.10 to 1.41) 
  sequence generation and allocation concealment 
 
0.94 (0.39 to 1.90) 
B2  sequence generation, in trials at low risk of bias for blinding 0.59 (0.14 to 1.46) 
  blinding, in trials at low risk of bias for sequence generation 1.01 (0.41 to 2.73) 
  sequence generation and blinding 
 
1.58 (0.59 to 4.65) 
B3  allocation concealment, in trials at low risk of bias for blinding 0.65 (0.20 to 2.14) 
  blinding, in trials at low risk of bias for allocation concealment 1.69 (0.44 to 5.68) 
  allocation concealment and blinding 
 
1.41 (0.55 to 4.02) 
B4  sequence generation, in trials at low risk of bias for allocation concealment & blinding 0.46 (0.11 to 1.13) 
  allocation concealment in trials at low risk of bias for sequence generation & blinding 0.49 (0.12 to 1.71) 
  blinding, in trials at low risk of bias for sequence generation & allocation concealment 0.99 (0.43 to 2.31) 
  sequence generation and allocation concealment, in trials at low risk of bias for blinding 0.39 (0.07 to 1.29) 
  sequence generation and blinding, in trials at low risk of bias for allocation concealment 1.44 (0.34 to 5.34) 
  allocation concealment and blinding, in trials at low risk of bias for sequence generation 0.50 (0.16 to 1.92) 
  sequence generation, allocation concealment and blinding 1.22 (0.39 to 3.01) 
λ ratio of heterogeneity variance among trials at high or unclear risk of bias to heterogeneity variance among trials at low risk of bias.   
*Note that results for multiple characteristics are not implied by the results for each individual bias domain in the multivariable analysis, due to the presence 
of all possible interactions between bias domains.
  
 
Multivariable analyses 
Also reported in Table 3 are results from multivariable analyses for the influence of accounting for 
combinations of design characteristics.  Based on results from fitting Model B1, heterogeneity among 
trials at high or unclear risk of bias for both sequence generation and allocation concealment is, on 
average, 94% that among trials at low risk of bias for both sequence generation and allocation 
concealment ( λˆ 0.94, 95% interval: 0.39 to 1.90).  Heterogeneity among trials at high or unclear risk 
of bias for both sequence generation and blinding is, on average, 58% greater than that among trials at 
low risk of bias for both characteristics based on results from fitting Model B2 ( λˆ 1.58, 95% interval: 
0.59 to 4.65).  Results from fitting Model B3 show that heterogeneity is, on average, 41% greater 
among trials at high or unclear risk of bias for both allocation concealment and blinding, compared 
with trials at low risk of bias for both characteristics ( λˆ 1.41, 95% interval: 0.55 to 4.02).  Results 
from multivariable analyses for the influence of accounting for all three design characteristics (Model 
B4) imply that heterogeneity is, on average, 22% greater among trials at high or unclear risk of bias 
(compared with low risk of bias) for all three reported design characteristics ( λˆ 1.22, 95% interval: 
0.39 to 3.01).  As in univariable analyses, estimates of association between heterogeneity and reported 
design characteristics are very uncertain; 95% credible intervals for λ all contain the null effect. 
 
Investigating the extent of heterogeneity due to reported trial design characteristics 
We investigate the extent to which one might expect between-trial heterogeneity in a random-effects 
meta-analysis to change, on average, if we adjust for potential bias attributable to specific design 
characteristics in a new meta-analysis.   
 
Table 4 summarises posterior medians of the proportion of total between-trial heterogeneity 
attributable to trials at high or unclear risk of bias across the subset of 117 meta-analyses in ROBES.   
 
Univariable analyses 
In univariable analyses for the influence of accounting for a single reported design characteristic, 
central estimates for the proportion of between-trial variance explained by trials at high or unclear risk 
of bias for sequence generation have median 30% (95% interval: 7% to 46%) across meta-analyses 
(Model A1).  There is less evidence that between-trial heterogeneity in a meta-analysis is attributable 
to the bias associated with low or unclear quality for allocation concealment; central estimates for the 
proportion of heterogeneity among trials at high or unclear risk of bias have median 6% (95% 
interval: 0% to 17%) across meta-analyses (Model A2).  Across meta-analyses, central estimates for 
the proportions of between-trial heterogeneity explained by bias associated with trials at high or 
unclear risk of bias for blinding have median 40% (95% interval: 8% to 56%) based on fitting Model 
A3.   
  
 
 
For each of the 117 meta-analyses included within the subset of ROBES, Figure 1 presents a 
comparison of the central estimate of heterogeneity variance among trials at low risk of bias and the 
central estimate of heterogeneity variance among all trials.  In separate univariable analyses for the 
influences of high or unclear risk of bias for sequence generation and blinding, the central estimate of 
heterogeneity variance among trials at low risk of bias tends to be lower than the central estimate of 
heterogeneity among all trials.  In contrast, the central estimate of heterogeneity variance among trials 
at low risk of bias for allocation concealment is slightly higher than that among all trials in 73 (62%) 
meta-analyses.   
 
Multivariable analyses 
Based on results from multivariable analyses for the influence of accounting for multiple reported 
design characteristics, one might hypothesize that heterogeneity among trials in meta-analyses within 
ROBES can be explained by the bias associated with sequence generation and/or allocation 
concealment (Model B1); across meta-analyses within the subset of ROBES, central estimates for the 
proportion of heterogeneity due to trials at high or unclear risk of bias have median 19% (95% 
interval: 0% to 48%).  Estimates of the proportion of heterogeneity due to trials at high or unclear risk 
of bias due to sequence generation and/or blinding have median 37% (95% interval: 0% to 57%) 
across meta-analyses (Model B2).  This median is slightly lower at 31% (95% interval: 0% to 51%) 
for heterogeneity variance explained by bias associated with trials at high or unclear risk of bias for 
allocation concealment and/or blinding (Model B3).  Across meta-analyses in ROBES, central 
estimates for the proportion of between-trial heterogeneity explained by bias associated with trials at 
high or unclear risk of bias for sequence generation, allocation concealment and/or blinding have 
median 37% (95% interval: 0% to 71%) based on fitting Model B4. 
 
In multivariable analyses for the influence of accounting for all three characteristics, the central 
estimate of heterogeneity variance among trials at low risk of bias for all three characteristics is lower 
than the central estimate of heterogeneity variance among all trials in the majority of 107 (91%) meta-
analyses (Figure 1).  
  
 
Table 4 Summaries of posterior medians for the proportion of heterogeneity due to trials at high or unclear risk of bias for each design characteristic and 
combinations of design characteristics within the subset of 117 meta-analyses extracted from ROBES. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Negative estimates suggest that heterogeneity among trials in a meta-analysis cannot be explained by trials at high or unclear risk of bias and were hence set 
to zero. 
Model Design characteristic/s 
Proportion of heterogeneity due to trials at high 
or unclear risk of bias for the design 
characteristic/s  * 
A1 Sequence generation Median 0.30; 95% interval 0.07 to 0.46 
A2 Allocation concealment Median 0.06; 95% interval 0 to 0.17 
A3 Blinding Median 0.40; 95% interval 0.08 to 0.56 
B1 Sequence generation and/or allocation concealment Median 0.19; 95% interval 0 to 0.48 
B2 Sequence generation  and/or blinding Median 0.37; 95% interval 0 to 0.57 
B3 Allocation concealment  and/or blinding Median 0.31; 95% interval 0 to 0.51 
B4 Sequence generation, allocation concealment  and/or blinding Median 0.37; 95% interval 0 to 0.71 
  
 
Figure 1 For each of the 117 meta-analyses within the subset of ROBES, the central estimate of heterogeneity variance among trials at low risk of bias plotted 
against the central estimate of heterogeneity variance among all trials.  Central estimates of heterogeneity variance are based on results from univariable 
model A1 for sequence generation, univariable model A2 for allocation concealment, univariable model A3 for blinding, and multivariable model B4 for 
sequence generation, allocation concealment and blinding.   Solid lines indicate that estimates are identical.  
 
  
 
Discussion  
Within-study biases can lead to overestimation or underestimation of the true intervention effect in a 
study and are expected to contribute to between-study variation in meta-analyses [5, 6, 16]. With 
access to a meta-epidemiological data set including meta-analyses which have implemented the 
Cochrane risk-of-bias tool, it was possible to explore the extent to which accounting for suspected 
biases influences levels of heterogeneity. We have investigated the impact of risk of bias judgments 
from Cochrane reviews for sequence generation, allocation concealment and blinding on between-trial 
heterogeneity, using data from 117 meta-analyses included in the ROBES study.   Between-trial 
heterogeneity in intervention effect is a common problem in meta-analysis.  The results of this 
empirical study show that roughly a third of between-trial heterogeneity might be explained by trial 
design characteristics, on average.  Prediction intervals are becoming increasingly widely used to 
provide a predicted range for the true intervention effect in an individual study [3, 17], and are useful 
in decision making [18].  The implications of our research are that prediction intervals for true effects 
could be narrowed to account for biases, if they are to represent genuine variation in true effects.  
 
This empirical study builds on previous meta-epidemiological studies [4-6] that have focussed on the 
influence of accounting for reported design characteristics on intervention effect rather than between-
trial heterogeneity.  Recent meta-epidemiological studies have tended to use the methods proposed by 
Welton et al.[8], which are less general in that they constrain trials at high or unclear risk of bias to be 
at least as heterogeneous as trials at low risk of bias.  We previously proposed a more general model 
for the analysis of meta-epidemiological data [9]. In this study, the advantage of using our model was 
that we could estimate the quantity λ, representing the ratio by which heterogeneity changes for trials 
at high or unclear risk of bias, compared to trials at low risk of bias. 
 
Random-effects meta-analysis may be appropriate when between-study heterogeneity exists.  
However, in some situations, studies differ substantially in quality so the random-effects assumption 
may be inadequate. When confronted with evidence of varying quality in practice, meta-analysts may 
decide to restrict their analyses to studies at lower risk of bias.  However, this would not be practical 
in the typical situation where few studies are available to be included in the meta-analysis.  The 
results of our meta-epidemiological study give some indication of increased heterogeneity among 
studies with high or unclear risk of bias judgements. These findings support recommendations to 
adjust for bias in meta-analyses of evidence of varying quality. Methods are available to adjust for and 
down-weight studies of lower quality in meta-analysis, using generic data-based evidence or expert 
opinion informed by detailed trial assessment [8, 19].  Based on our findings, these methods could be 
expected to reduce between-study variation in meta-analyses.  Since the between-study variance 
parameter would be imprecisely estimated in many meta-analyses that only contain a small number of 
  
 
studies, we recommend assigning an informative prior distribution to this parameter, based on 
empirical evidence from historical meta-analyses [1, 2]. 
 
For each reported design characteristic and combinations of design characteristics, we calculated the 
proportion of heterogeneity in each meta-analysis that could be explained by trials at high or unclear 
risk of bias.  Summaries of posterior medians for these proportions across meta-analyses give some 
indication of the reduction in between-trial heterogeneity we might expect to see in a meta-analysis, if 
we adjust for the bias associated with each reported design characteristic or combination of reported 
design characteristics.   There is empirical evidence to suggest that flaws in the random sequence 
generation and lack of blinding may lead to increased levels of heterogeneity among randomized 
controlled trials, on average, but flawed methods of allocation concealment might have little impact.  
These findings should be interpreted with caution due to the limited statistical power to detect 
differences in heterogeneity between higher and lower quality trials.  In each analysis the ratio of 
heterogeneity variance λ attributable to bias was very imprecisely estimated.  Although it would be 
expected for λ to be imprecisely estimated in a single meta-analysis, we hoped to gain precision when 
estimating across the collection of meta-analyses included in the ROBES database; however, 
variability across meta-analyses was high. 
 
In our analyses of the ROBES data, we wanted to allow the data to dominate and used a vague log-
normal(0,1) prior distribution for the heterogeneity parameter λ.  However, given the small amount of 
information available on λ in the dataset, there was a possibility that results could have been sensitive 
to the choice of vague prior distribution.  In an earlier paper, we used the same dataset in a sensitivity 
analysis to compare the effects of 5 different prior distributions for λ [9].  Posterior estimates for the 
scale parameter λ were consistent among the different priors, with similar medians and overlapping 
credible intervals.   
 
Heterogeneity among trials at low risk of bias could be explained by clinical differences, for example 
difference in participants, or in the dosage or timing of an intervention.  In each univariable and 
multivariable analysis, we did not find evidence of association between heterogeneity variance among 
trials at low risk of bias and the type of outcome under assessment in the meta-analysis.   This might 
be explained by the fact that the majority of the outcomes examined in the meta-analyses included in 
our analyses were subjectively measured.  In future work it would be of interest to explore how the 
extent of between-trial heterogeneity due to bias may depend on the type of outcome under 
assessment and the types of interventions being compared. 
 
Another limitation is the accuracy of reported design characteristics which may not well represent 
how a trial was actually conducted.  Trials that are conducted well could be poorly reported [20].  Hill 
  
 
et al. [21] investigated discrepancies between published reports and actual conduct of randomized 
clinical trials and found that sequence generation and allocation concealment were reported as unclear 
in over 75% of studies where these two characteristics were actually at low risk of bias.  A more 
recent study found that descriptions of blinding in trial protocols and corresponding reports were often 
in agreement [22]. These investigations provide some insight as to why the influences of accounting 
for high or unclear risk of bias for sequence generation and high or unclear risk of bias for allocation 
concealment on intervention effect and between-trial variance are smaller, compared with the effects 
of high or unclear risk of bias for blinding.  Ideally we would have investigated this further, by 
separating trials at unclear risk of bias from trials at high risk of bias and comparing heterogeneity 
estimates between trials at high risk of bias and trials at low or unclear risk of bias.  However the data 
on trials at high risk of bias were sparse. 
 
It is possible that our results were confounded by the influence of other types of biases that could not 
be accounted for in our analyses.  For example, there is empirical evidence of bias in the results of 
meta-analyses due to publication bias and selective reporting of outcomes arising from the lack of 
inclusion of statistically non-significant results [23, 24].  Methods to adjust for reporting biases are 
available, but it would have been impractical to apply these methods to each meta-analysis in our 
dataset.  Meta-analyses affected by reporting biases would be expected to overestimate intervention 
effect and so the extent of heterogeneity that we observed among trials in the ROBES database could 
be higher than expected. 
 
The ROBES dataset was extracted from the April 2011 issue of the Cochrane Database of Systematic 
Reviews, for which the risk of bias in trials may have been assessed prior to 2011.  As of early 2011, 
Cochrane review authors have assessed risk of bias due to blinding of participants and personnel 
separately from blinding of outcome assessors.  In the future, it would be of interest to investigate 
separate influences of accounting for blinding of participants and personnel and blinding of outcome 
assessors on intervention effect and between-trial heterogeneity, once large collections of meta-
analyses with such assessments become available.  It would also be of interest to investigate the 
impact of bias on intervention effect and heterogeneity in other types of meta-analyses; our analyses 
were conducted using binary outcome data from Cochrane reviews only.  These include a wide range 
of application areas but may not be representative of all healthcare meta-analyses, and so the findings 
in this paper may not be generalizable to meta-analyses included in other systematic reviews.   
 
In conclusion, the overall implications of this research are that the accuracy of meta-analysis results 
could be improved by adjusting for reported study design characteristics in the meta-analysis model. 
After conducting a random-effects meta-analysis, it is important to consider the potential effect of the 
intervention when it is applied within an individual study setting because this might be different from 
  
 
the average effect.   In the presence of substantial heterogeneity among studies, prediction intervals 
for the true intervention effect in an individual study will be wide and uncertain.  This empirical study 
gives some indication that adjustment for bias could reduce the uncertainty in predictive inferences, 
and better reflect the potential effectiveness of the intervention.  A strategy of including all studies 
with such adjustments may produce a more favourable trade-off between bias and precision than 
excluding studies assessed to be at high risk of bias.  However, interpretation of our results is limited 
by extremely imprecise estimates. 
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Supplementary materials  
 
S1 Estimating total heterogeneity variance from the label-invariant model 
We used label-invariant hierarchical models to analyse trial data from 117 meta-analyses in ROBES 
simultaneously.  The models have been proposed in an earlier paper [9], but we describe the models 
briefly here to show how to derive the formulae for heterogeneity variance 2 ,total mτ  among all trials in 
a meta-analysis m. 
S1.1 Univariable model for the influence of accounting for a single trial design characteristic 
In a given meta-analysis m, trials are categorised as low risk of bias (L-trials) or high/unclear risk of 
bias (H-trials) for a specific design characteristic.   
 
The L-trials provide an estimate of the underlying intervention effect θ Lim , assumed to have a normal 
random-effects distribution with mean md  and variance 2τm , specific to meta-analysis m.  The H-trials 
are assumed to estimate an underlying intervention effect θimH , assumed to be normally distributed 
with mean + mmd b and variance 2λτm :   
2
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~ ( , )
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im m m
im m m m
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N d
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θ τ
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The average bias bm in intervention effect in meta-analysis m is assumed to be exchangeable across 
meta-analyses, with overall mean b0 and between-meta-analysis variance in mean bias 2φ : 
2
0
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We set an indicator Xim to be 1 for H trials and 0 for L trials such that 
1
with probability
0 1 .
m
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m
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π

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Each trial is assumed to provide an underlying estimate of intervention effect: 
(1- )im im im
L
im i
H
mX Xθ θ θ= + . 
The first term of the sum will return θ Lim  if trial i is at low risk of bias. The second term will return 
θim
H  if the trial i is at high/unclear risk of bias.   
  
 
The total heterogeneity variance among trials in meta-analysis m is given by: 
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S1.2 Multivariable model for the influence of accounting for multiple trial design characteristics 
Suppose trials in a meta-analysis m are categorised as low risk of bias (L-trials) or high/unclear risk of 
bias (H-trials) for each of 2 reported design characteristics.  We set the indicator Xijm to be 1 for trials 
at high/unclear risk of bias for the j-th reported characteristic (j=1,2), and 0 for trials at low risk of 
bias for that characteristic such that 
1
with probability
0 1
jm
ijm
jm
X
π
π

= 
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Each trial is assumed to provide an estimate of underlying intervention effect: 
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Trials at low risk of bias for both characteristics 1 and 2 provide an estimate of intervention effect θ Lim
, as in Section S1.1.  The intervention effect θ1
H
im  in a trial i at high/unclear risk of bias for 
characteristic 1 but low risk of bias for characteristic 2 has a normal distribution with mean m 1md +b  
and variance 1.
2
mτ λ  The intervention effect θ2
H
im  in a trial i at high/unclear risk of bias for characteristic 
2 but low risk of bias for characteristic 1 has a normal distribution with mean m 2md +b  and variance 
2.
2
mτ λ  The intervention effect θ3
H
im  in a trial i at high/unclear risk of bias for both characteristics 1 and 
2 has a normal distribution with mean 3m 1m 2m md +b b+ b+  and variance 1 2 32mτ λ λ λ .  
 
  
  
 
An estimate of total heterogeneity variance among trials in meta-analysis m is given by: 
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In a similar way, we derive estimates of total heterogeneity in a meta-analysis from the multivariable 
label-invariant models for the influence of accounting for three design characteristics. 
  
  
 
S2 Model comparison 
 
Bayesian hierarchical models were fitted to trial data from all 117 meta-analyses.  The various models 
fitted to the data differed according to the indicators of design characteristics and interactions 
included as covariates in the model, and according to the inclusion of indicators of outcome type in 
the regression model for heterogeneity variance 2mτ  among trials at low risk of bias.  Results to 
compare model fit are given in Table S1.   
 
 
 
 
  
 
 Table S1 Posterior mean residual deviance Dres, effective number of parameters pD and deviance information criterion (DIC) for the hierarchical 
models fitted to the ROBES data. 
 
Model Design characteristic/s 
Interaction/s 
between design 
characteristics 
Covariates in 
model for τ2 Dres pD DIC 
A1 Sequence generation N/A - 2982 1909 4891 Sequence generation N/A Outcome type 3000 1889 4889 
A2 Allocation concealment N/A - 2972 1914 4886 Allocation concealment N/A Outcome type 3003 1899 4902 
A3 Blinding N/A - 2968 1915 4883 Blinding N/A Outcome type 3003 1891 4894 
B1 Sequence generation and allocation concealment Yes - 3001 1900 4901 Sequence generation and allocation concealment No - 2988 1906 4894 
B2 Sequence generation and blinding Yes - 2978 1908 4886 Sequence generation and blinding No - 2988 1904 4892 
B3 Allocation concealment and blinding Yes - 2996 1902 4898 Allocation concealment and blinding No - 2981 1908 4889 
B4 
Sequence generation,  allocation concealment and blinding All possible - 2985 1905 4890 
Sequence generation,  allocation concealment and blinding 
Interaction 
between 
sequence 
generation and 
blinding alone 
- 2998 1899 4897 
Sequence generation,  allocation concealment and blinding No - 2978 1913 4891 
Sequence generation,  allocation concealment and blinding No Outcome type 2991 1895 4886 
